Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) have earned a consensus rating of “Moderate Buy” from the eighteen analysts that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and fifteen have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $699.6429.
MDGL has been the subject of several analyst reports. Piper Sandler reaffirmed an “overweight” rating on shares of Madrigal Pharmaceuticals in a research note on Wednesday, June 24th. HC Wainwright reiterated a “buy” rating on shares of Madrigal Pharmaceuticals in a research report on Friday, July 31st. Barclays reduced their target price on shares of Madrigal Pharmaceuticals from $964.00 to $962.00 and set an “overweight” rating on the stock in a research note on Monday, August 3rd. Wolfe Research upgraded shares of Madrigal Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $605.00 price target on the stock in a report on Tuesday, August 4th. Finally, Truist Financial raised their price objective on shares of Madrigal Pharmaceuticals from $640.00 to $709.00 and gave the stock a “buy” rating in a research note on Wednesday, May 13th.
Get Our Latest Stock Analysis on MDGL
Insider Buying and Selling at Madrigal Pharmaceuticals
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System raised its stake in shares of Madrigal Pharmaceuticals by 54,067.5% during the second quarter. California State Teachers Retirement System now owns 9,233,929 shares of the biopharmaceutical company’s stock valued at $4,958,158,000 after acquiring an additional 9,216,882 shares in the last quarter. Janus Henderson Group PLC increased its position in Madrigal Pharmaceuticals by 27.4% during the 1st quarter. Janus Henderson Group PLC now owns 2,018,647 shares of the biopharmaceutical company’s stock valued at $1,051,727,000 after purchasing an additional 433,804 shares during the period. Jupiter Topco LLC bought a new stake in shares of Madrigal Pharmaceuticals in the 2nd quarter valued at about $1,039,650,000. Paulson & CO. Inc. bought a new stake in shares of Madrigal Pharmaceuticals in the 2nd quarter valued at about $719,524,000. Finally, BlackRock Inc. purchased a new stake in shares of Madrigal Pharmaceuticals in the 2nd quarter worth approximately $644,753,000. Hedge funds and other institutional investors own 98.50% of the company’s stock.
Madrigal Pharmaceuticals Trading Down 0.3%
MDGL stock opened at $541.08 on Monday. The firm has a fifty day moving average price of $529.90 and a 200 day moving average price of $505.01. Madrigal Pharmaceuticals has a fifty-two week low of $393.61 and a fifty-two week high of $615.00. The firm has a market cap of $12.50 billion, a PE ratio of -41.98 and a beta of -0.98. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.94 and a current ratio of 3.20.
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.99) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.68) by $0.69. Madrigal Pharmaceuticals had a negative net margin of 25.32% and a negative return on equity of 56.65%. The company had revenue of $364.25 million for the quarter, compared to the consensus estimate of $352.13 million. During the same quarter in the prior year, the firm earned ($1.90) earnings per share. Madrigal Pharmaceuticals’s revenue was up 71.2% on a year-over-year basis. Sell-side analysts anticipate that Madrigal Pharmaceuticals will post -7.03 earnings per share for the current fiscal year.
Madrigal Pharmaceuticals Company Profile
Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.
The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.
Featured Stories
- Five stocks we like better than Madrigal Pharmaceuticals
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
